Review

Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy

Hisashi Yokoshiki, MD, PhD\textsuperscript{a,}\* Hirofumi Mitsuyama, MD, PhD\textsuperscript{b}, Masaya Watanabe, MD, PhD\textsuperscript{a}, Takeshi Mitsuhashi, MD, PhD\textsuperscript{b}, Akihiko Shimizu, MD, PhD\textsuperscript{c}

\textsuperscript{a}Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Japan
\textsuperscript{b}Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
\textsuperscript{c}Faculty of Health Sciences, Yamaguchi Graduate School of Medicine, Japan

\textbf{A R T I C L E  I N F O}

Article history:
Received 9 January 2017
Received in revised form
5 March 2017
Accepted 14 March 2017
Available online 21 April 2017

Keywords:
Cardiac resynchronization therapy
CRT
Ischemic cardiomyopathy
Non-ischemic cardiomyopathy
Reverse remodeling
Implantable cardioverter-defibrillator
ICD

\textbf{A B S T R A C T}

Cardiac resynchronization therapy (CRT) using a biventricular pacing system has been an effective therapeutic strategy in patients with symptomatic heart failure with a reduced left ventricular ejection fraction (LVEF) of 35% or less and a QRS duration of 130 ms or more. The etiology of heart failure can be classified as either ischemic or non-ischemic cardiomyopathy. Ischemic etiology of patients receiving CRT is prevalent predominantly in North America, moderately in Europe, and less so in Japan. CRT reduces mortality similarly in both ischemic and non-ischemic cardiomyopathy, whereas reverse structural left ventricular remodeling occurs more favorably in non-ischemic cardiomyopathy. Because the substrate for ventricular arrhythmias appears to be more severe in cases of ischemic as compared with non-ischemic cardiomyopathy, the use of an implantable cardioverter-defibrillator (ICD) backup method could prolong the long-term survival, especially of patients with ischemic cardiomyopathy, even in the presence of CRT. The aim of this review article is to summarize the effects of CRT on outcomes and the role of ICD backup in ischemic and non-ischemic cardiomyopathy.

© 2017 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\begin{table}[h]
\begin{tabular}{|l|}
\hline
Contents lists available at ScienceDirect \\
Journal of Arrhythmia 33 (2017) 410–416 \\
\hline
\end{tabular}
\end{table}

1. Introduction ................................................. 410
2. Current guidelines and appropriate use criteria for CRT ................................................. 411
3. Proportion of ischemic and non-ischemic etiology in CRT recipients in North America, Europe, and Japan ................................................. 411
4. Reverse remodeling with CRT in ischemic and non-ischemic cardiomyopathy ................................................. 411
5. The effects of CRT on morbidity and mortality in ischemic and non-ischemic cardiomyopathy ................................................. 411
6. The role of a defibrillator in ischemic and non-ischemic heart failure patients receiving CRT ................................................. 412
7. Promising strategies for better response to CRT in ischemic cardiomyopathy ................................................. 413
8. Conclusions .................................................. 415
Conflict of interest ............................................. 415
Acknowledgments ............................................. 415
References ..................................................... 415

1. Introduction

Cumulative survival from all-cause mortality decreases proportionally with QRS duration in patients with advanced heart failure [1]. Prolongation of QRS duration with left bundle-branch block (LBBB) morphology imposes left ventricle (LV) activation delay via a transmural functional line of block located between the LV septum and the lateral wall [2], resulting in ventricular dyssynchrony. Optimization of cardiac performance had been proposed by use of biventricular pacing in patients with drug-refractory congestive heart failure and an intraventricular conduction delay using the epicardial [3,4] and subsequently, a transvenous route with electrodes selectively inserted in the cardiac veins through coronary

*Correspondence to: Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan. Fax: +81 11 706 7874.
E-mail address: yokoshiki@med.hokudai.ac.jp (H. Yokoshiki).
sinus over the LV free wall [5]. The MIRACLE (Multicenter InSync Randomized Clinical Evaluation) study proved the clinical benefits of atrial-synchronized biventricular pacing in patients with moderate-to-severe heart failure (New York Heart Association (NYHA) class III or IV) who had a left ventricular ejection fraction (LVEF) of 35% or less and a QRS interval of 130 ms or more [6]. This biventricular pacing system has been called cardiac resynchronization therapy (CRT), and become an established therapeutic approach for symptomatic heart failure with prolonged QRS duration.

With regards to mortality, the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) study demonstrated for the first time a better prognosis of patients with CRT plus a defibrillator (CRT-D) than those using optimal pharmacologic therapy alone [7]. In the subgroup analyses, hazard ratios for death from any cause of CRT-D as compared with pharmacologic therapy were 0.73 (95% confidence interval [CI], 0.52 to 1.04, P = 0.082) and 0.50 (95% CI, 0.29 to 0.88, P = 0.015) in ischemic and non-ischemic cardiomyopathy, respectively. A test for the interaction between the treatment effects and the etiology of cardiomyopathy was not significant [7]. In the Cardiac Resynchronization – Heart Failure (CARE-HF) study, CRT reduced all-cause mortality similarly in both ischemic and non-ischemic cardiomyopathy [8,9]. In agreement, the survival benefit with CRT-D over an implantable cardioverter-defibrillator (ICD) was consistent in a subgroup analysis of patients with ischemic cardiomyopathy and in those with non-ischemic cardiomyopathy [10,11]. This review article aims to summarize the effects of CRT on outcomes and the importance of ICD backup in ischemic and non-ischemic cardiomyopathy.

2. Current guidelines and appropriate use criteria for CRT

According to current guidelines in the United State (US) and Europe, CRT is indicated as class I (i.e., a procedure or treatment that should be performed where the benefits outweigh the risks) for patients who have LVEF of 35% or less: LBBB with a QRS duration of 150 ms [12] (130 ms [13]) or greater; and NYHA class II, III, or ambulatory IV symptoms on guideline-directed medical therapy. In addition, CRT may be considered to be appropriate for patients who have LVEF of 30% or less, LBBB with a QRS duration of 150 ms or greater, and NYHA class I, if the etiology of heart failure is ischemic [14]. The latter recommendation is based on the limited data from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study, in which patients with ischemic cardiomyopathy and NYHA class I were enrolled in about 15% of total subjects [11]. In MADIT-CRT, patients with ischemic or non-ischemic cardiomyopathy, LVEF of 30% or less, and a QRS duration of 130 ms or more, were randomly assigned to receive CRT plus a defibrillator (CRT-D), or an ICD alone. CRT-D (compared with ICD) was found to reduce the primary endpoint, death from any cause or a nonfatal heart-failure event (hazard ratio in the CRT-D group, 0.66; 95% CI, 0.52 to 0.84; P = 0.001). In this regard, the MADIT-CRT study demonstrated the effectiveness of CRT in combination with a defibrillator; that is, (a) the treatment of heart failure with reverse remodeling by using CRT, and (b) the primary prevention of sudden cardiac death by using a defibrillator.

3. Proportion of ischemic and non-ischemic etiology in CRT recipients in North America, Europe, and Japan

The rate of ischemic heart failure patients was over 50% in most of the randomized studies of CRT conducted in North America and Europe [6,7,10,11,15–17], except for 36% in CARE-HF (Cardiac Resynchronization – Heart Failure) [8] (Table 1). This trend is consistent with that in a cohort study using the National Impatient Sample (NIS), which is the publicly-available healthcare database in the United States (US) [18]. It is interesting to know that the CARE-HF study enrolled patients at only European centers, and that the CeRtiTuDe cohort study [19], which enrolled ischemic cardiomyopathy less than 50%, was also conducted in Europe. In contrast, patients with non-ischemic cardiomyopathy were most common at a rate of about 70% in Japan, on the basis of the Japan Cardiac Device Treatment Registry (JCDTR) database [20] (Table 1, Fig. 1).

With regard to medication, patients in the cohort studies were less likely to receive angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin receptor blockers (ARB) and/or beta-blockers compared with those in the contemporary randomized studies.

4. Reverse remodeling with CRT in ischemic and non-ischemic cardiomyopathy

The rate of responders assessed by the improvement of NYHA class status in the MIRACLE study was 67% in the CRT group, and was significantly higher than that (38%) in the control group [6]. More objectively, patients with echocardiographic changes of 25% (or 15% [21]) reduction in left ventricular end-systolic volume (LVEV), 15% reduction in left ventricular end-diastolic volume (LVEDV), 20% reduction in left atrial volume (LAV) and/or 8% increase in LVEF, a year following CRT, have been considered to show favorable responses and significant reverse remodeling [22].

Gasparini et al. reported for the first time that patients with non-ischemic etiology had a greater increase in LVEF and a decrease in NYHA functional class after CRT than did patients with ischemic heart disease [23]. Sub-analysis of the prospective randomized studies including MIRACLE (Multicenter InSync Randomized Clinical Evaluation) [24], CARE-HF [9], REVERSE (REsynchronization reVErse Remodeling in Systolic left vEntricular dysfunction) [25] and MADIT-CRT [22] confirmed the occurrence of more favorable reverse remodeling in non-ischemic than in ischemic cardiomyopathy (Table 2).

Goldenberg et al. identified factors associated with reverse remodeling following CRT using data from MADIT-CRT, and created a response score [26] (Table 3). They proposed a combined assessment of these factors for improved selection of patients for CRT. A similar analysis was performed for predicting patients with LVEF normalization (≥ 50%), which found a total of six relevant factors: female gender, non-ischemic etiology, LBBB, baseline LVEF > 30%, LVEV ≤ 170 mL and LAV index ≤ 45 mL/m² [27]. Therefore, it is an undoubted fact that non-ischemic cardiomyopathy shows a better response with regard to reverse LV structural remodeling than ischemic cardiomyopathy (Fig. 2).

5. The effects of CRT on morbidity and mortality in ischemic and non-ischemic cardiomyopathy

On the basis of sub-analysis of the CARE-HF study, CRT decreased the primary composite endpoint (i.e., all-cause mortality or hospitalization for a major cardiovascular event) and principal secondary endpoint (i.e., all-cause mortality) in both ischemic and non-ischemic cardiomyopathy [9]. Patients with ischemic etiology were older, with a higher prevalence of male gender, and were more likely to be NYHA class IV, indicating the presence of more advanced heart failure. The authors concluded (a) the benefits of CRT in patients with or without ischemic heart disease were similar in relative terms, (b) but as patients with...
ischemic heart disease had a worse prognosis, the benefit for them in absolute terms may be greater. However, it is interesting to know the marginal statistical significance of interaction \((P = 0.06)\) between ischemic and non-ischemic cardiomyopathy, in terms of two hazard functions for the primary composite end points (ischemic: hazard ratio 0.72; 95% CI: 0.54–0.95; non-ischemic: hazard ratio 0.48; 95% CI: 0.35–0.65) [9].

Barsheshet et al. sought to identify factors associated with a reduction in heart failure or death in response to CRT-D as compared with ICD in the MADIT-CRT study [22]. Such factors in ischemic cardiomyopathy were (a) QRS duration \(\geq 150\) ms, (b) systolic blood pressure \(< 115\) mmHg and (c) LBBB, whereas in non-ischemic cardiomyopathy, (a) females, (b) patients with diabetes mellitus and (c) LBBB showed a favorable clinical response [22] (Table 4).

Meta-analysis using individual patient-data from five randomized trials, with adjustment of the baseline variables including age, sex, NYHA class, etiology, QRS morphology and duration, LVEF and systolic blood pressure, concluded that only QRS duration \((\geq 140\) ms), and not the etiology of heart failure, predicted the magnitude of the effects of CRT on morbidity and mortality [28]. Taken together, CRT appears to reduce the mortality of both groups similarly.

### Table 1

The rate of ischemic etiology and medications in clinical studies of CRT.

| Study (published year) | (Number of patients) | Follow-up (mo.) | Isch. | ACEI/ARB | Beta. | MRA | CRT-P vs Control | CRT-D vs Control | HR | 95% CI | \(P\) |
|-----------------------|----------------------|----------------|-------|----------|-------|-----|----------------|----------------|-----|--------|-----|
| MIRACLE (2002) (n=453) | 6                    | NYHA III, IV   | LVEF \(\geq 35\) % | CRT-D vs CRT-P | HR 0.65 (95% CI 0.37–0.96) | \(P\) = 0.03 |
| MIRACLE-ICD (2003) (n=325) | 6                    | NYHA III, IV   | LVEF \(\geq 35\) % | CRT-D vs CRT-P | HR 0.64 (95% CI 0.48–0.86) | \(P\) = 0.003 |
| COMPANION (2004) (n=1520) | 15                   | NYHA III, IV   | LVEF \(\geq 35\) % | CRT-D vs CRT-P | HR 0.76 (95% CI 0.58–1.01) | \(P\) = 0.059 |
| CARE-HF (2005) (n=813) | 29                   | NYHA III, IV   | LVEF \(\geq 35\) % | CRT-D vs CRT-P | HR 0.64 (95% CI 0.48–0.85) | \(P\) = 0.003 |
| REVERSE (2008) (n=610) | 12                   | NYHA I, II     | LVEF \(\geq 40\) % | CRT-D vs CRT-P | HR 0.76 (95% CI 0.58–1.01) | \(P\) = 0.003 |

### 6. The role of a defibrillator in ischemic and non-ischemic heart failure patients receiving CRT

Witt et al. reported that CRT-D reduced mortality as compared with CRT-P (biventricular pacemaker without a defibrillator) in an observational study that enrolled 917 heart failure patients (427 with non-ischemic, and 490 with ischemic cardiomyopathy) who had LVEF of 35% or less and a QRS duration of 120 ms or greater [29]. However, only patients with ischemic etiology, benefited significantly from a defibrillator. In addition, even in the cases of responders (who were defined by an improvement of NYHA functional class at the six-month follow-up visit with CRT), ICD backup (CRT-D) was a predictor of longer survival in patients with ischemic cardiomyopathy [29]. A similar retrospective study by Kutyifa et al. concluded that CRT-D in ischemic cardiomyopathy was associated with a mortality benefit as compared with CRT-P, but no benefit of CRT-D over CRT-P in mortality was observed in non-ischemic cardiomyopathy [30] (Table 5). A meta-analysis of effects of ICD backup in CRT recipients revealed significant associations between male gender or ischemic cardiomyopathy and a stronger benefit of CRT-D [31].
Factors associated with reduction of heart failure or death with CRT-D versus ICD in each etiology group.

| Study      | Measured at (months) | Etiology | ⊥LVEDV | ⊥LVESV | ⊥LVEF |
|------------|----------------------|----------|--------|--------|-------|
| MIRACLE    | 12                   | Ischemic | Decrease | Decrease | Increase |
|            | [24]                 | Non-ischemic | NS | NS | Increase |
| REVERSE    | 12                   | Ischemic | Decrease | Decrease | Increase |
|            | [25]                 | Non-ischemic | Decrease | Decrease | Increase |
| CARE-HF    | 18                   | Ischemic | Decrease | Decrease | Increase |
|            | [9]                  | Non-ischemic | Decrease | Decrease | Increase |
| MADIT-CRT  | 12                   | Ischemic | Decrease | Decrease | Increase |
|            | [22]                 | Non-ischemic | Decrease | Decrease | Increase |

Isch: ischemic cardiomyopathy; Non-isch: non-ischemic cardiomyopathy; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; ⊥: change from baseline; NS: not significant.

The degree of these changes was greater in non-ischemic vs ischemic cardiomyopathy when the between-group comparison was significant (i.e., * or †). * P < 0.05 for interaction or between-group (ischemic vs non-ischemic) comparison.
† P < 0.005 for interaction or between-group (ischemic vs non-ischemic) comparison.

In contrast to ischemic etiology [32–34], the efficacy of ICD implantation for the primary prevention of sudden cardiac death was conflicting in non-ischemic cardiomyopathy [35–39] (Table 6). The DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality) recently demonstrated that the addition of ICD function fails to prolong survival in symptomatic heart failure patients with non-ischemic cardiomyopathy who have LVEF of 35% or less [38]. In this study, the rate of patients who had CRT was 58%, and the effects of ICD implantation was independent of CRT status (P = 0.73 for the interaction). Therefore, it appears that the arrhythmogenic substrate itself is more severe in cases of ischemic cardiomyopathy, compared with that of non-ischemic cardiomyopathy.

7. Promising strategies for better response to CRT in ischemic cardiomyopathy

Bleeker et al. reported that presence of transmural scar tissue in the posterolateral LV segments (where a LV lead was implanted most frequently [40]) often resulted in clinical and echocardiographic nonresponse to CRT in ischemic cardiomyopathy [41]. Moreover, using two-dimensional speckle tracking imaging, LV lead position at the myocardial scar or discordant area (which is outside the latest activated segment) were independent

This table was made based on the data from Barsheshet et al. [22].

In contrast to ischemic etiology [32–34], the efficacy of ICD implantation for the primary prevention of sudden cardiac death was conflicting in non-ischemic cardiomyopathy [35–39] (Table 6). The DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality) recently demonstrated that the addition of ICD function fails to prolong survival in symptomatic heart failure patients with non-ischemic cardiomyopathy who have LVEF of 35% or less [38]. In this study, the rate of patients who had CRT was 58%, and the effects of ICD implantation was independent of CRT status (P = 0.73 for the interaction). Therefore, it appears that the arrhythmogenic substrate itself is more severe in cases of ischemic cardiomyopathy, compared with that of non-ischemic cardiomyopathy.

Table 4
Factors associated with reduction of heart failure or death with CRT-D versus ICD

| Etiology                        | Hazard ratio (95% confidence interval) | P value | Interaction |
|---------------------------------|---------------------------------------|---------|-------------|
| Ischemic cardiomyopathy         |                                       |         |             |
| QRS ≥ 150 ms                    | 0.53 (0.38–0.73)                      | < 0.001 | P = 0.04    |
| QRS < 150 ms                    | 0.89 (0.60–1.31)                      | 0.55    |             |
| Systolic blood pressure         |                                       |         |             |
| < 115 mmHg                      | 0.48 (0.32–0.72)                      | < 0.001 | P = 0.05    |
| Systolic blood pressure > 115 mmHg | 0.80 (0.58–1.11) | 0.18   |             |
| LBBB                            | 0.47 (0.34–0.65)                      | < 0.001 | P = 0.002   |
| Non-LBBB                        | 1.09 (0.72–1.65)                      | 0.68    |             |
| Non-ischemic cardiomyopathy     |                                       |         |             |
| Female                          | 0.25 (0.14–0.46)                      | < 0.001 | P = 0.001   |
| Male                            | 0.90 (0.54–1.46)                      | 0.67    |             |
| Diabetes mellitus (+)           | 0.31 (0.16–0.61)                      | < 0.001 | P = 0.05    |
| Diabetes mellitus (–)           | 0.67 (0.44–1.04)                      | 0.08    |             |
| LBBB                            | 0.42 (0.28–0.62)                      | < 0.001 | P = 0.011   |
| Non-LBBB                        | 1.57 (0.61–4.04)                      | 0.35    |             |

This table was made based on the data from Barsheshet et al. [22].
determinants of worse prognosis during the long-term follow-up in ischemic heart failure patients treated with CRT [42].

A strategy to implant a LV lead to the latest activated segment was effective in reducing the primary composite endpoint of mortality and heart failure hospitalization in the TARGET (Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy) [43] and STARTER (Speckle Tracking Assisted Resynchronization Therapy for Electrode Region) [44] studies. A sub-analysis of STARTER reported that echocardiography-guided LV lead placement improved CRT-D therapy (shock or anti-tachycardia pacing)-free survival more favorably in patients with ischemic cardiomyopathy to a level comparable to that of non-ischemic etiology [45]. As such, further clinical studies are required to determine whether the echocardiography-guided LV lead implantation reduces the incidence of sustained ventricular arrhythmias in patients with ischemic cardiomyopathy.

Optimization of ativoventricular, as well as interventricular, delay shortens isovolumic contraction time, thereby increasing the effective diastolic filling time and the stroke volume [46]. Marsan et al. reported that the optimization of sequential biventricular

Table 5
Studies and Ischemic Etiology Comparing Outcomes with CRT-D Versus CRT-P.

| Study (year) | F/U (mo.) | Number of patients | Isch. | Male | Age (years) | NYHA | Mortality with CRT-D vs CRT-P |
|--------------|-----------|--------------------|-------|------|-------------|------|----------------------------|
| RCT          |           | CRT-D 595          | 55%   | 67%  | 66          | III 86| CRT-D vs Ctrl, HR 0.64 (95% CI 0.48-0.86), P=0.003 |
|              |           | CRT-P 617          | 54%   | 67%  | 67          | III 87| CRT-P vs Ctrl, HR 0.76 (95% CI 0.58-1.01), P=0.059 |
|              |           | Ctrl 308           | 59%   | 69%  | 68          | III 82| CRT-P vs Ctrl, HR 0.76 (95% CI 0.58-1.01), P=0.059 |
| REVERSE (2013) (n = 419) [57] | 60 | CRT-D 345          | 59%   | 79%  | 63          | II 82| Decrease in mortality |
|              |           | CRT-P 74           | 46%   | 72%  | 64          | II 81| HR 0.35 (95% CI 0.17-0.69), P=0.003 |
| MASCOT (2013) (n = 402) [58] | 12 | CRT-D 228          | 60%   | 86%  | 68          | III 87| Lack of decrease in mortality |
|              |           | CRT-P 174          | 38%   | 70%  | 68          | III 83| Lack of decrease in mortality |
| Observational study |          |                    |       |      |             |      |                                |
| Contak IR (2013) (n = 374) [59] | 55 | CRT-D 266          | 62%   | 85%  | 67          | III 61| Decrease in mortality |
|              |           | CRT-P 108          | 41%   | 68%  | 74          | III 64| HR 0.51 (95% CI 0.32-0.83), P=0.007 |
| Kutyifa et al (2014) (n = 1122) [30] | 28 | CRT-D 429          | 51%   | 84%  | 64          | III 64| Decrease in mortality of Isch |
|              |           | CRT-P 693          | 34%   | 71%  | 66          | III 63| CRT-P vs Ctrl, HR 0.65 (95% CI 0.40-0.98), P=0.003 |
| Barra et al (2016) (n = 638) [62] | 49 | CRT-D 224          | 61%   | 88%  | 66          | III 76| CRT-P vs Ctrl, HR 0.98 (95% CI 0.73-1.32), P=0.084 |
|              |           | CRT-P 414          | 48%   | 73%  | 70          | III 76| CRT-P vs Ctrl, HR 0.76 (95% CI 0.60-0.97), P=0.032 |
| Munir (2016) (n = 512) [63] | 41 | CRT-D 405          | 57%   | 73%  | 81          | III 76| CRT-P vs Ctrl, HR 0.98 (95% CI 0.73-1.32), P=0.094 |
|              |           | CRT-P 107          | 30%   | 64%  | 83          | III 76| CRT-P vs Ctrl, HR 0.76 (95% CI 0.60-0.97), P=0.032 |

F/U: follow-up period; mo.: months; Isch: ischemic cardiomyopathy; CRT-P: CRT pacemaker; CRT-D: CRT with a defibrillator; Ctrl: control (without CRT devices); RCT: randomized controlled trial; HR: hazard ratio; 95% CI: 95% confidence interval; MASCOT: Management of Atrial Fibrillation Suppression in AF-HF Comorbidity Therapy; Contak IR: Contak Italian Registry; Isch: ischemic cardiomyopathy; GS: Goldenberg risk score. The Goldenberg risk score model comprised five clinical factors including (i) NYHA class > II, (ii) AF, (iii) QRS duration > 120 ms, (iv) age > 70 years and (v) blood urea nitrogen (BUN) > 26 mg/dL. [64].

Table 6
Randomized controlled trials for primary prevention of sudden cardiac death by ICD in non-ischemic cardiomyopathy.

| n     | NYHA class | LVEF | Death from any cause (ICD vs Control) | Other |
|-------|------------|------|---------------------------------------|-------|
| CAT   | 104        | II, III | ≤ 30% | Lack of decrease in mortality |       |
| AMIOVIRT [39] | 103 | I, II, III | ≤ 35% | Lack of decrease in mortality |       |
| DEFINITE [37] | 458 | I, II, III | ≤ 35% | HR 0.65; 95% CI 0.40–0.106; P = 0.08 | No mortality benefit in NYHA II |
| SCD-HeFT [36] | 2521 | II, III | ≤ 35% | HR 0.77; 95% CI 0.62–0.96; P = 0.007 | No mortality benefit in NYHA III |
| DANISH [38] | 1116 | II, III, IV | ≤ 35% | HR 0.85; 95% CI 0.56–1.28; P = 0.435 | CTR 58% |

Table 6
Randomized controlled trials for primary prevention of sudden cardiac death by ICD in non-ischemic cardiomyopathy.

| n     | NYHA class | LVEF | Death from any cause (ICD vs Control) | Other |
|-------|------------|------|---------------------------------------|-------|
| CAT   | 104        | II, III | ≤ 30% | Lack of decrease in mortality |       |
| AMIOVIRT [39] | 103 | I, II, III | ≤ 35% | Lack of decrease in mortality |       |
| DEFINITE [37] | 458 | I, II, III | ≤ 35% | HR 0.65; 95% CI 0.40–0.106; P = 0.08 | No mortality benefit in NYHA II |
| SCD-HeFT [36] | 2521 | II, III | ≤ 35% | HR 0.77; 95% CI 0.62–0.96; P = 0.007 | No mortality benefit in NYHA III |
| DANISH [38] | 1116 | II, III, IV | ≤ 35% | HR 0.85; 95% CI 0.56–1.28; P = 0.435 | CTR 58% |

n: number of patients; CAT: Cardiomyopathy Trial; AMIOVIRT: Amiodarone Versus Implantable Cardioverter-Defibrillator; DEFINITE: Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; SCD-HeFT: Sudden Cardiac Death in Heart Failure Trial; DANISH: Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality; HR: hazard ratio; 95% CI: 95% confidence interval.

* Except for SCD-HeFT, the etiology of cardiomyopathy in eligible subjects was non-ischemic in CAT, AMIOVIRT, DEFINITE, and DANISH. Proportion of non-ischemic etiology was 48% in SCD-HeFT.
pacing via adjustment of the V-V interval further increased LV systolic performance, particularly in ischemic cardiomyopathy [47]. They also found that the degree of pre-stimulation of the LV was positively correlated with an amount of scar volume with regard to its optimization.

An LV lead that is designed with four electrodes is capable of delivering two LV pulses per pacing cycle when it is connected to a CRT device with the ability to deliver multipoint pacing (MPP) [48–50]. Clinical data is accumulating regarding the long-term effects of MPP. Mainly in Europe, the responder rate has been reported to be higher (76% [49], 90% [50]) in patients with MPP than those (about 60% [49,50]) with conventional CRT. Although MPP did not further improve acute hemodynamic response in patients who responded favorably to conventional biventricular pacing [51,52], non-responders with non-LBBB appeared most likely to derive benefit from use of MPP [51]. In addition, a heart model in silico predicted that MPP offered an improved response over conventional CRT in cases in which a larger scar was present in the posterolateral region [53]. Consistently, in patients with ischemic cardiomyopathy in whom the LV lead was deployed over an LV free wall scar, MPP proved to be the most optimal, as compared with single-site LV pacing methods, in terms of acute hemodynamic response [52]. We anticipate that MPP is superior to conventional CRT, especially in patients with ischemic cardiomyopathy and a large scar in the LV free wall.

8. Conclusions

The effects of CRT on mortality are not heterogeneous among patients with ischemic and non-ischemic cardiomyopathy. In contrast, it appears that CRT offers a more favorable response with regard to reverse LV remodeling in cases of non-ischemic cardiomyopathy. Furthermore, the substrate for ventricular arrhythmias in ischemic cardiomyopathy appears to be more severe compared with non-ischemic etiology, thereby playing an essential role of ICD backup, especially in cases of ischemic cardiomyopathy. Both the implantation of an LV lead to the latest activated segment and MPP via a quadrupolar LV lead are promising concepts for an improved response to CRT in ischemic cardiomyopathy.

Conflict of interest

All authors declare no conflicts of interest related to this study.

Acknowledgments

H Yokoshiki thanks Dr. Masayuki Sakurai, Director of Hokko Memorial Hospital, for constant encouragement of this work.

References

[1] Gottipaty VK, Krelis SP, Lu F, et al. The resting electrocardiogram provides a sensitive and inexpensive marker of prognosis in patients with chronic congestive heart failure. J Am Coll Cardiol 1999;33:145.
[2] Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004;109:1133–9.
[3] Bakker PF, Meiburg H, de Jonge N, et al. Beneficial effects of biventricular pacing in congestive heart failure. PACE 1994;17:820.
[4] Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994;17:1974–5.
[5] Daubert JC, Ritter P, Le Breton H, et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol 1998;21:239–45.
[6] Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–53.
[7] Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–50.
[8] Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–49.
[9] Wikstrom G, Blomstrom-Lundqvist C, Anderson B, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 2009;30:782–8.
[10] Goldenberg I, Kuttyla V, Klein HO, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1094–701.
[11] Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329–38.
[12] Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;2013(128):e249–327.
[13] Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J 2016;38(37):2129–2183.
[14] Russo AM, Stainback RF, Bailey SR, et al. ACCF/AHA/ESC/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society for Cardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol, 61; 2013. p. 1318–68.
[15] Lind C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834–43.
[16] Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385–95.
[17] Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the UNICORIC ICD Trial. Circulation 2009;120:2695–703.
[18] Lindvall C, Chatterjee NA, Chang Y, et al. National Trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation 2016;133:273–81.
[19] Marjon E, Leclercq C, Narayanam K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the GErITube cohort study. Eur Heart J 2015;36:2767–76.
[20] Yokoshiki H, Shimizu A, Mitsuhashi T, et al. Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: analysis of the Japanese national cardiac registry database. J Arrhythm 2016;32:486–90.
[21] Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPect) trial. Circulation 2008;117:2608–16.
[22] Barshiret A, Goldenberg I, Moss AJ, et al. Response to preventive cardiac resynchronization therapy in patients with ischemic and nonischemic cardiomyopathy in MADIT-CRT. Eur Heart J 2011;32:1622–30.
[23] Gasparini M, Mantica M, Galimberti P, et al. Is the outcome of cardiac resynchronization therapy related to the underlying etiology? Pacing Clin Electrophysiol 2003;26:175–80.
[24] St John Sutton M, Plappert T, Hilipsch KE, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Circulation 2006;113:266–72.
[25] St John Sutton M, Chio S, Plappert T, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class III heart failure. Circulation 2009;120:1836–45.
[26] Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;124:1527–36.
[27] Ruwald MH, Solomon SD, Foster E, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014;130:2278–86.
[28] Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547–56.
[29] Witt CT, Kronberg MB, Nohr EA, et al. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischemic, but not in non-ischaemic cardiomyopathy. Europace 2016;18:413–9.
[30] Kuttyla V, Geller I, Bogyi P, et al. Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization...
therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail 2014;16:1323–30.

[31] Barra S, Providencia R, Tang A, et al. Importance of implantable cardioverter-defibrillator back-up in cardiac resynchronization therapy recipients: a systematic review and meta-analysis. J Am Heart Assoc 2015;4:e002529.

[32] Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–40.

[33] Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.

[34] Ant Y, Ando K, Soga Y, et al. Mortality and prediction of appropriate implantable cardioverter-defibrillator therapy in Japanese patients with Multicenter Automatic Defibrillator Implantation Trial II criteria. J Arrhythm 2017;33:17–22.

[35] Bansch D, Antz M, Boczar S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453–8.

[36] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.

[37] Kober L, Thune JJ, Nielsen JC, et al. Deªbrillator therapy with pacemaker on mortality in heart failure patients: results of a Japanese online registry database. J Arrhythmology 2008;24:133–40.

[38] Shimizu A, Nitta T, Kurita T, et al. Current status of implantable deªbrillator devices in patients with left ventricular dysfunction - The first report from the online registry database. J Arrhythmology 2008;24:138–40.

[39] Shimizu A, Nitta T, Kurita T, et al. Actual conditions of implantable deªbrillator therapy over 5 years in Japan. J Arrhythmology 2012;28:263–72.

[40] Gold MR, Daubert JC, Abraham WT, et al. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythmology Electrophysiol 2013;6:1613–8.

[41] Delgado V, van Bommel RJ, Bertini M, et al. Relative merits of left ventricular dysynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation 2011;123:70–8.

[42] Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:1509–18.

[43] Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the Speciªle Tracking Assisted Resynchronization Therapy for Electrode Region trial. Circ Heart Fail 2013;6:427–34.

[44] Abu Daya H, Alam MB, Adelstein E, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy in ischemic vs non-ischemic cardiomyopathy patients. Heart Rhythm 2014;11:614–5.

[45] Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchrony by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002;105:438–45.

[46] Marson NA, Bleeke GB, Van Bommel RJ, et al. Cardiac resynchronization therapy in patients with ischemic versus non-ischemic heart failure: differential effect of optimizing interventricular pacing interval. Am Heart J 2009;158:703–76.

[47] Forleo GB, Santini L, Gammaria M, et al. Multipoint pacing via a quadripolar left-ventricular lead: preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP). EuropACE 2016 [May 17. [Epub ahead of print].

[48] Popone C, Calovic Z, Vicedomini G, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: twelve-month follow-up study. Heart Rhythm 2015;12:1250–8.

[49] Kanon F, Marcantonio L, Baracca E, et al. Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response to cardiac resynchronization therapy at 1 year. Heart Rhythm 2016;13:1644–51.

[50] Sohal M, Shetty A, Niederer S, et al. Mechanistic insights into the beneªts of multisite pacing in cardiac resynchronization therapy: the importance of electrical substrate and rate of left ventricular activation. Heart Rhythm 2015;12:2449–57.

[51] Kumar F, Taylor RJ, Stegmann B, et al. Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. EuropACE 2016;18:1227–34.

[52] Niederer SA, Shetty AK, Plank G, et al. Biophysical modeling to simulate the response to multisite left ventricular stimulation using a quadripolar pacing lead. Pacing Clin Electrophysiol 2012;35(2):204–14.

[53] Shimizu A, Mitsuhashi T, Furushima H, et al. Current status of cardiac resynchronization therapy with defibrillators and factors inºuencing its progression in Japan. J Arrhythmology 2013;29:168–74.

[54] Shimizu A, Nitta T, Kurita T, et al. Current status of implantable deªbrillator devices in patients with left ventricular dysfunction - The first report from the online registry database. J Arrhythmology 2008;24:138–40.

[55] Shimizu A, Nitta T, Kurita T, et al. Actual conditions of implantable deªbrillator therapy over 5 years in Japan. J Arrhythmology 2012;28:26–72.

[56] Gold MR, Daubert JC, Abraham WT, et al. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythmology Electrophysiol 2013;6:1613–8.

[57] Schuchert A, Muto C, Maonins T, et al. Lead complications, device infections, and clinical outcomes in the ﬁrst year after implantation of cardiac resynchronization therapy-deªbrillator and cardiac resynchronization therapy-pacemaker. EuropACE 2013;15:71–6.

[58] Morani G, Gasparini M, Zanot F, et al. Cardiac resynchronization therapy-deªbrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. EuropACE 2013;15:1273–9.

[59] Looi KL, Gajendragadkar PR, Khan FZ, et al. Cardiac resynchronization therapy: pacemaker versus internal cardioverter-deªbrillator in patients with impaired left ventricular function. Heart 2014;100:794–9.

[60] Reitan C, Chaudhry U, Bakos Z, et al. Long-term results of cardiac resynchronization therapy-deªbrillator in patients receiving cardiac resynchronization therapy. EuropACE 2013;15:1284–6.

[61] Munir MB, Althouse AD, Rijal S, et al. Clinical characteristics and outcomes of older cardiac resynchronization therapy recipients using a pacemaker versus a deªbrillator. J Cardiovasc Electrophysiol 2016;27:730–4.

[62] Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratiªcation for primary implantation of a cardioverter-deªbrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288–96.